Aura Biosciences, Inc.
General ticker "AURA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $412.6M (TTM average)
Aura Biosciences, Inc. follows the US Stock Market performance with the rate: 40.1%.
Estimated limits based on current volatility of 2.7%: low 6.12$, high 6.45$
Factors to consider:
- Total employees count: 113 (+6.6%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Going concern doubt, Product development failure, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.96$, 8.63$]
- 2026-12-31 to 2027-12-31 estimated range: [3.86$, 8.43$]
Financial Metrics affecting the AURA estimates:
- Negative: with PPE of -3.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Operating cash flow
- Positive: Investing cash flow per share per price, % of 10.27 > 2.08
- Positive: 69.38 < Shareholder equity ratio, % of 80.81 <= 81.92
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0
Short-term AURA quotes
Long-term AURA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $84.99MM | $96.12MM | $112.79MM |
| Operating Income | $-84.99MM | $-96.12MM | $-112.79MM |
| Non-Operating Income | $8.72MM | $9.31MM | $6.71MM |
| R&D Expense | $65.23MM | $73.30MM | $90.30MM |
| Income(Loss) | $-76.27MM | $-86.81MM | $-106.08MM |
| Taxes | $0.14MM | $0.11MM | $0.11MM |
| Net Income(Loss)* | $-76.41MM | $-86.92MM | $-106.19MM |
| Stockholders Equity | $225.85MM | $151.97MM | $136.91MM |
| Assets | $255.07MM | $182.50MM | $169.43MM |
| Operating Cash Flow | $-63.85MM | $-79.81MM | $-84.74MM |
| Capital expenditure | $0.71MM | $1.25MM | $0.45MM |
| Investing Cash Flow | $-113.96MM | $68.82MM | $35.59MM |
| Financing Cash Flow | $97.29MM | $1.59MM | $77.16MM |
| Earnings Per Share** | $-1.93 | $-1.75 | $-1.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.